JP2008532523A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008532523A5 JP2008532523A5 JP2008500966A JP2008500966A JP2008532523A5 JP 2008532523 A5 JP2008532523 A5 JP 2008532523A5 JP 2008500966 A JP2008500966 A JP 2008500966A JP 2008500966 A JP2008500966 A JP 2008500966A JP 2008532523 A5 JP2008532523 A5 JP 2008532523A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- acid sequence
- cell
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 21
- 102000003735 Mesothelin Human genes 0.000 claims 11
- 108090000015 Mesothelin Proteins 0.000 claims 11
- 108091033319 polynucleotide Proteins 0.000 claims 11
- 102000040430 polynucleotide Human genes 0.000 claims 11
- 239000002157 polynucleotide Substances 0.000 claims 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 239000002246 antineoplastic agent Substances 0.000 claims 6
- 229940127089 cytotoxic agent Drugs 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 4
- 239000012642 immune effector Substances 0.000 claims 4
- 229940121354 immunomodulator Drugs 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000003966 growth inhibitor Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 230000005907 cancer growth Effects 0.000 claims 1
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66017705P | 2005-03-10 | 2005-03-10 | |
| US60/660,177 | 2005-03-10 | ||
| PCT/US2006/008598 WO2006099141A2 (en) | 2005-03-10 | 2006-03-09 | Anti-mesothelin antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011290449A Division JP5378497B2 (ja) | 2005-03-10 | 2011-12-29 | 抗メソテリン抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008532523A JP2008532523A (ja) | 2008-08-21 |
| JP2008532523A5 true JP2008532523A5 (https=) | 2009-07-30 |
| JP4949373B2 JP4949373B2 (ja) | 2012-06-06 |
Family
ID=36992268
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008500966A Expired - Lifetime JP4949373B2 (ja) | 2005-03-10 | 2006-03-09 | 抗メソテリン抗体 |
| JP2011290449A Expired - Lifetime JP5378497B2 (ja) | 2005-03-10 | 2011-12-29 | 抗メソテリン抗体 |
| JP2013168325A Expired - Lifetime JP5788443B2 (ja) | 2005-03-10 | 2013-08-13 | 抗メソテリン抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011290449A Expired - Lifetime JP5378497B2 (ja) | 2005-03-10 | 2011-12-29 | 抗メソテリン抗体 |
| JP2013168325A Expired - Lifetime JP5788443B2 (ja) | 2005-03-10 | 2013-08-13 | 抗メソテリン抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US7592426B2 (https=) |
| EP (2) | EP1861425B1 (https=) |
| JP (3) | JP4949373B2 (https=) |
| AU (2) | AU2006223301B2 (https=) |
| CA (1) | CA2600505C (https=) |
| ES (2) | ES2429340T3 (https=) |
| WO (1) | WO2006099141A2 (https=) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1648511A1 (en) * | 2003-07-29 | 2006-04-26 | Morphotek, Inc. | Antibodies and methods for generating genetically altered antibodies with enhanced effector function |
| EP3101034A1 (en) | 2004-02-12 | 2016-12-07 | Morphotek, Inc. | Monoclonal antibodies that specifically bind to folate receptor alpha |
| EP1861425B1 (en) | 2005-03-10 | 2012-05-16 | Morphotek, Inc. | Anti-mesothelin antibodies |
| CA2607444C (en) | 2005-04-22 | 2015-03-10 | Morphotek, Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
| KR100694508B1 (ko) * | 2005-05-24 | 2007-03-13 | 울산대학교 산학협력단 | Ｈｂｂｋ４항체를 포함하는 암 질환 치료용 약학조성물및 이를 이용한 암의 면역치료 방법 |
| US7943133B2 (en) | 2006-02-02 | 2011-05-17 | Boston Biocom Llc | Mesothelin antibody protein fusions and methods of use |
| US7795411B2 (en) | 2006-10-05 | 2010-09-14 | Fred Hutchinson Cancer Research Center | Vectors for expressing in vivo biotinylated recombinant proteins |
| CN111518218A (zh) * | 2006-11-02 | 2020-08-11 | 阿塞勒隆制药公司 | Alk1受体和配体拮抗剂及其用途 |
| ES2526355T3 (es) | 2007-10-01 | 2015-01-09 | Bristol-Myers Squibb Company | Anticuerpos humanos que se adhieren a mesotelina, y usos de los mismos |
| MX2010005603A (es) | 2007-11-26 | 2010-08-02 | Bayer Schering Pharma Ag | Anticuerpos antimesotelina y usos de los mismos. |
| CA2718321A1 (en) * | 2008-03-27 | 2009-10-01 | Dimiter S. Dimitrov | Human anti-mesothelin monoclonal antibodies |
| JP2010014691A (ja) * | 2008-06-20 | 2010-01-21 | Igaku Seibutsugaku Kenkyusho:Kk | 腹水中のメソテリン及び／又は巨核球増強因子を検出するための方法、キット、試薬及び装置 |
| EP2411416A1 (en) * | 2009-03-24 | 2012-02-01 | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services | Anti-mesothelin antibodies |
| AR076284A1 (es) * | 2009-04-29 | 2011-06-01 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
| HUE036157T2 (hu) * | 2010-03-30 | 2018-06-28 | Janssen Biotech Inc | Humanizált IL-25 ellenanyagok |
| BR112013014527A2 (pt) | 2010-12-20 | 2017-03-07 | Genentech Inc | anticorpo isolado, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica, uso do imunoconjugado, método para tratamento de um indivíduo que tem um câncer positivo para mesotelina, para inibição de proliferação de uma célula positiva para mesotelina, para detecção de mesotelina humana em uma amostra biológica e para detectar um câncer positivo para mesotelina |
| US10233240B1 (en) * | 2011-04-18 | 2019-03-19 | The Regents Of The University Of California | Methods for treating cholestatic liver fibrosis |
| SG194787A1 (en) | 2011-05-06 | 2013-12-30 | Us Gov Health & Human Serv | Recombinant immunotoxin targeting mesothelin |
| SG11201404354UA (en) * | 2012-02-17 | 2014-10-30 | Seattle Genetics Inc | ANTIBODIES TO INTEGRIN αVβ6 AND USE OF SAME TO TREAT CANCER |
| WO2013142300A2 (en) * | 2012-03-20 | 2013-09-26 | Biogen Idec Ma Inc. | Jcv neutralizing antibodies |
| ES2731757T3 (es) | 2012-03-20 | 2019-11-18 | Biogen Ma Inc | Anticuerpos neutralizantes de JCV |
| EP2828290B1 (en) | 2012-03-23 | 2018-08-15 | The United States of America, represented by the Secretary, Department of Health and Human Services | Anti-mesothelin chimeric antigen receptors |
| WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
| EP3327037B1 (en) * | 2012-08-21 | 2019-10-09 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Mesothelin domain-specific monoclonal antibodies and use thereof |
| PT3221356T (pt) | 2014-11-20 | 2020-10-29 | Hoffmann La Roche | Moléculas de ligação ao antigénio biespecíficas ativadoras das células t contra folr1 e cd3 |
| DK3221357T3 (da) | 2014-11-20 | 2020-08-10 | Hoffmann La Roche | Fælles letkæder og fremgangsmåder til anvendelse |
| WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| PL3298033T5 (pl) | 2015-05-18 | 2023-10-30 | TCR2 Therapeutics Inc. | Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych |
| WO2017032293A1 (zh) * | 2015-08-21 | 2017-03-02 | 科济生物医药（上海）有限公司 | 抗间皮素全人抗体以及靶向间皮素的免疫效应细胞 |
| KR101782487B1 (ko) * | 2015-09-24 | 2017-09-27 | 재단법인 목암생명과학연구소 | 신규 항-메소텔린 항체 및 이를 포함하는 조성물 |
| JP2018536389A (ja) * | 2015-10-02 | 2018-12-13 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | メソテリンとｃｄ３に結合する二重特異性細胞活性化抗原結合分子 |
| MX389194B (es) * | 2015-10-06 | 2025-03-20 | Univ Minnesota | Compuestos terapéuticos y métodos. |
| RU2018127657A (ru) | 2015-12-30 | 2020-01-31 | Новартис Аг | Виды терапии на основе иммуноэффекторных клеток с улучшенной эффективностью |
| KR20180118175A (ko) | 2016-03-04 | 2018-10-30 | 노파르티스 아게 | 다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도 |
| JP7015244B2 (ja) | 2016-03-22 | 2022-02-02 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | プロテアーゼ活性化ｔ細胞二重特異性分子 |
| WO2017162587A1 (en) * | 2016-03-22 | 2017-09-28 | F. Hoffmann-La Roche Ag | Protease-activated t cell bispecific molecules |
| EP3432924A1 (en) | 2016-03-23 | 2019-01-30 | Novartis AG | Cell secreted minibodies and uses thereof |
| CN109715808A (zh) | 2016-04-15 | 2019-05-03 | 诺华股份有限公司 | 用于选择性蛋白质表达的组合物和方法 |
| JP7160683B2 (ja) * | 2016-04-29 | 2022-10-25 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 術後癒着の予防及び治療のための方法及び組成物 |
| BR112018074453A2 (pt) * | 2016-05-27 | 2019-03-19 | Abbvie Biotherapeutics Inc. | proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral |
| SG11201811184UA (en) | 2016-06-20 | 2019-01-30 | F Star Beta Ltd | Lag -3 binding members |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| BR112019002035A2 (pt) | 2016-08-01 | 2019-05-14 | Novartis Ag | tratamento de câncer usando um receptor de antígeno quimérico em combinação com um inibidor de uma molécula pró-macrófago m2 |
| CA3032498A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| WO2018067993A1 (en) | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
| JP7291396B2 (ja) | 2016-11-22 | 2023-06-15 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法 |
| EP4649966A3 (en) | 2016-12-01 | 2026-02-18 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging |
| ES2912408T3 (es) | 2017-01-26 | 2022-05-25 | Novartis Ag | Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos |
| WO2018232020A1 (en) | 2017-06-13 | 2018-12-20 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| EP3728316B1 (en) | 2017-12-19 | 2025-02-26 | invoX Pharma Limited | Fc binding fragments comprising a pd-l1 antigen-binding site |
| WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| EP3788369A1 (en) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| EP3801769A1 (en) | 2018-05-25 | 2021-04-14 | Novartis AG | Combination therapy with chimeric antigen receptor (car) therapies |
| WO2019237035A1 (en) | 2018-06-08 | 2019-12-12 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
| EP3806889A4 (en) * | 2018-06-18 | 2022-07-13 | Anwita Biosciences, Inc. | CYTOKI FUSION PROTEINS AND USES THEREOF |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| PT3820569T (pt) | 2018-07-12 | 2025-01-14 | Invox Pharma Ltd | Moléculas de anticorpo que se ligam a pd-l1 e cd137 |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| ES3044118T3 (en) | 2018-07-12 | 2025-11-26 | Invox Pharma Ltd | Antibody molecules that bind cd137 and ox40 |
| KR20210069048A (ko) | 2018-08-30 | 2021-06-10 | 티씨알2 테라퓨틱스 인크. | 융합 단백질을 이용하는 tcr 재프로그래밍을 위한 조성물 및 방법 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CN112912400B (zh) | 2018-10-19 | 2025-05-30 | 明尼苏达大学董事会 | Nk接合子分子及其使用方法 |
| WO2020092631A1 (en) * | 2018-10-31 | 2020-05-07 | Fred Hutchinson Cancer Research Center | Compositions and methods for detecting and treating cancers characterized by expression of mesothelin |
| KR20210106437A (ko) | 2018-12-20 | 2021-08-30 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물 |
| CN109705219B (zh) * | 2019-01-08 | 2020-11-13 | 上海霖科生物科技有限公司 | 与间皮素结合的单克隆抗体及其制备方法 |
| CA3123519A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| CN113490528B (zh) | 2019-02-15 | 2024-12-03 | 诺华股份有限公司 | 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| KR20220035908A (ko) * | 2019-06-19 | 2022-03-22 | 실버백 테라퓨틱스, 인크. | 항-메소텔린 항체 및 이의 면역접합체 |
| US11827709B2 (en) | 2019-12-05 | 2023-11-28 | Seagen Inc. | Anti-AVB6 antibodies and antibody-drug conjugates |
| IL293640A (en) | 2019-12-20 | 2022-08-01 | Amgen Inc | CD40 antagonistic mesothelin-targeted multispecific antibody constructs for the treatment of solid tumors |
| BR112022011902A2 (pt) | 2019-12-20 | 2022-09-06 | Novartis Ag | Terapias de combinação |
| JP2023529211A (ja) | 2020-06-11 | 2023-07-07 | ノバルティス アーゲー | Ｚｂｔｂ３２阻害剤及びその使用 |
| KR20230027056A (ko) | 2020-06-23 | 2023-02-27 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 |
| JP7819176B2 (ja) | 2020-08-03 | 2026-02-24 | ノバルティス アーゲー | ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用 |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| TW202321296A (zh) | 2021-10-06 | 2023-06-01 | 美商鏈接免疫療法公司 | 抗間皮素抗原結合分子及其用途 |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| AU2024260837A1 (en) | 2023-04-25 | 2025-10-16 | Arsenal Biosciences, Inc. | Novel receptors for transcription regulation |
| PE20252789A1 (es) | 2023-05-24 | 2025-12-22 | Kumquat Biosciences Inc | Compuestos heterociclicos y usos de estos |
| WO2025235862A1 (en) | 2024-05-10 | 2025-11-13 | Inndura Therapeutics Inc. | A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4694778A (en) | 1984-05-04 | 1987-09-22 | Anicon, Inc. | Chemical vapor deposition wafer boat |
| US4851332A (en) | 1985-04-01 | 1989-07-25 | Sloan-Kettering Institute For Cancer Research | Choriocarcinoma monoclonal antibodies and antibody panels |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| WO1992007081A2 (en) | 1990-10-12 | 1992-04-30 | THE UNITED STATES OF AMERICA as represented by TH E SECRETARY, U.S. DEPARTMENT OF COMMERCE | A monoclonal antibody |
| US5646253A (en) | 1994-03-08 | 1997-07-08 | Memorial Sloan-Kettering Cancer Center | Recombinant human anti-LK26 antibodies |
| US6074643A (en) | 1993-09-09 | 2000-06-13 | Cli Oncology, Inc. | Site-directed chemotherapy of metastases |
| US6191268B1 (en) | 1993-12-17 | 2001-02-20 | Dana-Farber Cancer Institute | Compositions and methods relating to DNA mismatch repair genes |
| CA2182206A1 (en) | 1994-01-27 | 1995-08-03 | William A. Haseltine | Human dna mismatch repair proteins |
| DE19513676A1 (de) | 1995-04-11 | 1996-10-17 | Behringwerke Ag | Cytoplasmatische Expression von Antikörpern, Antikörperfragmenten und Antikörperfragmentfusionsmolekülen in E.coli |
| DE19541844C1 (de) | 1995-11-09 | 1997-07-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung |
| ATE254931T1 (de) | 1996-01-05 | 2003-12-15 | Us Gov Health & Human Serv | Mesothelinantigen, verfahren und testsatz zur targetierung |
| AU719513B2 (en) | 1996-05-04 | 2000-05-11 | Astrazeneca Ab | Monoclonal antibody to CEA, conjugates comprising said antibody, and their therapeutic use in an adept system |
| US6312731B1 (en) | 1997-08-29 | 2001-11-06 | Southern Research Institute | Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of using thereof |
| US6809184B1 (en) | 1997-12-01 | 2004-10-26 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use |
| EP1025230B1 (en) | 1997-12-01 | 2006-02-08 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | ANTIBODIES, INCLUDING Fv MOLECULES, AND IMMUNOCONJUGATES HAVING HIGH BINDING AFFINITY FOR MESOTHELIN AND METHODS FOR THEIR USE |
| US6146894A (en) | 1998-04-14 | 2000-11-14 | The Johns Hopkins University | Method for generating hypermutable organisms |
| US7745159B2 (en) * | 1999-02-26 | 2010-06-29 | Nathalie B Scholler | Methods and compositions for diagnosing carcinomas |
| US6365410B1 (en) | 1999-05-19 | 2002-04-02 | Genencor International, Inc. | Directed evolution of microorganisms |
| EP2011801A1 (en) | 1999-05-27 | 2009-01-07 | Government of the United States as represented by the Secretary, Department of Health and Human Services | Immunoconjugates having high binding affinity |
| AU2001275267A1 (en) | 2000-06-05 | 2001-12-17 | Corixa Corporation | Leader peptides for enhancing secretion of recombinant protein from a host cell |
| US6808894B1 (en) | 2000-11-07 | 2004-10-26 | Morphotek, Inc. | Methods for generating genetically altered antibody producing cell lines with improved antibody characteristics |
| WO2002054856A1 (en) | 2001-01-15 | 2002-07-18 | Morphotek Inc. | Chemical inhibitors of mismatch repair |
| AU2002258518A1 (en) | 2001-03-14 | 2002-09-24 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer |
| EP1258255A1 (en) | 2001-05-18 | 2002-11-20 | Boehringer Ingelheim International GmbH | Conjugates of an antibody to CD44 and a maytansinoid |
| AR036154A1 (es) | 2001-05-18 | 2004-08-18 | Boehringer Ingelheim Pharma | Anticuerpos especificos de cd44v6. |
| US20060127894A1 (en) | 2001-08-08 | 2006-06-15 | Incyte Corporation | Protein associated with cell growth, differentiation, and death |
| WO2004009782A2 (en) | 2002-07-19 | 2004-01-29 | Morphotek, Inc. | Methods for generating enhanced antibody-producing cell lines with improved growth characteristics |
| WO2005014652A1 (en) | 2003-08-05 | 2005-02-17 | Morphotek, Inc. | A variant cell surface molecule associated with cancer |
| EP1861425B1 (en) * | 2005-03-10 | 2012-05-16 | Morphotek, Inc. | Anti-mesothelin antibodies |
| CA2607444C (en) | 2005-04-22 | 2015-03-10 | Morphotek, Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
-
2006
- 2006-03-09 EP EP06737748A patent/EP1861425B1/en not_active Expired - Lifetime
- 2006-03-09 US US11/373,546 patent/US7592426B2/en active Active
- 2006-03-09 WO PCT/US2006/008598 patent/WO2006099141A2/en not_active Ceased
- 2006-03-09 EP EP10180413.6A patent/EP2322560B1/en not_active Expired - Lifetime
- 2006-03-09 ES ES10180413T patent/ES2429340T3/es not_active Expired - Lifetime
- 2006-03-09 CA CA2600505A patent/CA2600505C/en not_active Expired - Lifetime
- 2006-03-09 JP JP2008500966A patent/JP4949373B2/ja not_active Expired - Lifetime
- 2006-03-09 ES ES06737748T patent/ES2386367T3/es not_active Expired - Lifetime
- 2006-03-09 AU AU2006223301A patent/AU2006223301B2/en not_active Expired
-
2009
- 2009-08-21 US US12/545,369 patent/US8206710B2/en active Active
-
2011
- 2011-01-24 AU AU2011200251A patent/AU2011200251B2/en not_active Expired
- 2011-12-29 JP JP2011290449A patent/JP5378497B2/ja not_active Expired - Lifetime
-
2012
- 2012-05-21 US US13/476,656 patent/US8481703B2/en not_active Expired - Lifetime
-
2013
- 2013-03-13 US US13/799,766 patent/US8658173B2/en not_active Expired - Lifetime
- 2013-08-13 JP JP2013168325A patent/JP5788443B2/ja not_active Expired - Lifetime
-
2014
- 2014-01-06 US US14/148,011 patent/US9115197B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008532523A5 (https=) | ||
| JP2012100677A5 (https=) | ||
| US11981723B2 (en) | Method of targeting exosomes | |
| RU2764031C2 (ru) | Конъюгаты антител с лекарственными средствами, характеризующиеся высокой in vivo переносимостью | |
| ES2595091T3 (es) | Composiciones farmacéuticas con resistencia a CEA soluble | |
| JP2007504280A5 (https=) | ||
| JP2016503295A5 (https=) | ||
| JP2009539380A5 (https=) | ||
| JP2010535713A5 (https=) | ||
| JP2013121353A5 (https=) | ||
| RU2013107776A (ru) | Антитело к противоопухолевому антигену и способы применения | |
| HRP20160270T1 (hr) | Monoklonska antitijela protiv glipikana-3 | |
| PE20200839A1 (es) | Anticuerpos anti-cd137 | |
| JP2010111679A5 (https=) | ||
| JP2011505146A5 (https=) | ||
| CA2595610A1 (en) | Antibodies directed to angiopoietin-2 and uses thereof | |
| JP2017500028A (ja) | 新規の抗ｄｐｅｐ３抗体および使用方法 | |
| JP2011502517A5 (https=) | ||
| MX2010008570A (es) | Anticuerpos alfa5-beta1 y sus usos. | |
| JP2009521206A5 (https=) | ||
| US20160130359A1 (en) | Her2-specific monoclonal antibodies and conjugates thereof | |
| JP2024544520A5 (https=) | ||
| JP2014515600A5 (https=) | ||
| JP2008508858A5 (https=) | ||
| JP2023511554A (ja) | インテグリンαｖβ８に結合する抗体およびその使用 |